BRCA2 and hypoparathyroidism-retardation-dysmorphism syndrome: HRDCNA provides a new direction for effectively validating the pathogenicity of uncertain important variants (VUS) of BRCA1 and BRCA2, and suggests the major genetic basis for human HRD.